Group 1 - The QDII funds have shown impressive performance since 2025, with an average net value increase of 27.9%, particularly driven by funds heavily invested in Hong Kong innovative pharmaceuticals [2] - Notable funds such as Huatai-PB Korea Semiconductor ETF and E Fund Global Growth Select Mixed A have seen net value increases of 127.55% and 102.91% respectively, with several other funds also exceeding 80% growth [2] - The top holdings of these high-performing funds predominantly include Hong Kong innovative pharmaceutical stocks, with examples like Kelun-Botai Biotech and Innovent Biologics among the top five holdings of Huatai-PB Hong Kong Advantage Select Mixed A [2] Group 2 - The technology sector is also a key focus for many high-performing products, with E Fund Global Growth Select Mixed A holding major global tech stocks such as TSMC and Google-A among its top ten holdings [3] - Fund managers express optimism for the future of the innovative pharmaceutical and technology sectors, citing a recent phase of adjustment in the innovative drug industry as a temporary market sentiment issue rather than a fundamental change [4][5] - The innovative drug sector's valuation has become attractive, with expectations of upward potential, and the industry is anticipated to show resilience and technological attributes over the next 2 to 3 years [5] Group 3 - The pharmaceutical industry is expected to see positive changes in 2026, with contract development organizations (CXO) gaining confidence from solid data, and new technologies like artificial intelligence and brain-machine interfaces opening new application scenarios [5] - The semiconductor sector, particularly in storage, is projected to continue its cycle, with local market trends favoring leading storage manufacturers and potential IPOs supporting capacity expansion [6]

Market Overview - The pharmaceutical sector is experiencing a structural bull market in 2025, with the CITIC Pharmaceutical Index rising nearly 30% in the first three quarters, driven by the global recognition of the value of innovative drugs and devices [2][3] - The industry is expected to enter a critical phase of innovation realization and global expansion in 2026, shifting investment logic from expectation-driven to closely tracking clinical data, commercialization progress, and international achievements [2][3] Valuation Insights - The pharmaceutical sector's valuation remains at historical lows, with significant investment opportunities still available. As of December 31, 2025, various sub-sectors are trading at relatively low valuations, such as biopharmaceuticals at 35.16X and medical devices at 33.07X [7][9] - The medical services, chemical raw materials, and chemical preparations sectors have shown impressive growth, with increases of 29.22%, 22.03%, and 20.44% respectively [7] Revenue and Profit Trends - From January to November 2025, China's pharmaceutical manufacturing industry reported total revenue of 220.65 billion yuan, a year-on-year decline of 2.51%, while total profit decreased by 1.79% [9] - The performance of the biopharmaceutical, medical services, and pharmaceutical distribution sectors has improved, with biopharmaceuticals benefiting from rapid drug volume growth post-collection [9] Fund Management and Investment Opportunities - As of the end of Q3 2025, public funds' holdings in the pharmaceutical sector were at 11.22%, below the ten-year average of 8.15%, indicating potential for excess returns as the sector approaches a performance inflection point [11] - The low allocation of public funds and the sector's historical low valuations present significant opportunities for investment in high-potential sub-sectors and individual stocks [11] Innovation and Policy Support - The Chinese biopharmaceutical industry is entering a new phase of high-quality development, with significant improvements in innovation capabilities among the top 100 pharmaceutical companies [14][21] - The government has implemented comprehensive policies to support the development of innovative drugs and medical devices, transitioning from single-item support to a full-chain, regional, and financial support system [15][28] Global Market Position - China has become the second-largest market for innovative drug launches globally, contributing approximately 30% of the world's innovative pipelines as of Q3 2025 [50][66] - The country is increasingly recognized for its efficiency and cost-effectiveness in drug development, with a significant number of clinical trials initiated in China, particularly in oncology [53][66] Licensing and Commercialization Trends - The number of license-out transactions for Chinese innovative drugs has surged, with 103 deals recorded in the first three quarters of 2025, totaling $92.03 billion, marking a 77% increase year-on-year [43][63] - The successful inclusion of innovative drugs in the new commercial insurance directory is expected to enhance their commercialization prospects [30] Future Growth Areas - Next-generation therapies, including ADCs, bispecific antibodies, and cell and gene therapies, are becoming focal points for research and investment, with China leading in these areas [76][87] - The oncology drug market is projected to reach $441 billion, with new therapies expected to account for about 20% of treatment expenditures by 2029 [82]

Market Performance - After a six-day decline, the Hong Kong Stock Connect Innovation Drug ETF (520880) rebounded on January 23, rising over 2% at one point and closing up 1.53% with a trading volume of 348 million yuan [1][6] - Major constituent stocks such as Cloudtop New Drug led the gain with an 8.2% increase, while other key stocks like Kangfang Biotech and Shiyao Group also saw positive performance [1][6] Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued a document promoting high-quality development in the pharmaceutical retail sector, encouraging innovative drugs and reference preparations to enter retail pharmacy sales channels [3][9] - This policy is expected to provide a pathway for high-value innovative drugs, such as CAR-T, to fill the insurance coverage gap through commercial insurance directories [3][9] - The insurance industry association estimates that by 2025, the total compensation amount for innovative drugs and devices from commercial health insurance will reach approximately 14.7 billion yuan, with a compound annual growth rate of 70% over four consecutive years [3][9] Industry Trends - At the recent JPM conference, Chinese pharmaceutical companies showcased technological breakthroughs in areas such as ADC, IO dual antibodies, and GLP-1, moving towards global markets through licensing and collaborative development [3][9] - According to CITIC Securities, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation effectiveness [3][9] Investment Opportunities - The Hong Kong Stock Connect Innovation Drug ETF (520880) is highlighted as a high-elasticity T+0 investment tool, with its index featuring three unique advantages: 1. Purely innovative drugs with 100% purity, covering companies focused on drug development [5][11] 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5][11] 3. Enhanced risk control through forced de-weighting of less liquid constituent stocks [5][11] Constituent Stocks - The top ten constituent stocks of the Hong Kong Stock Connect Innovation Drug ETF (520880) have a combined weight of 73.41%, showcasing significant leadership in the sector [6][12] - Notable stocks include: - Kangfang Biotech (10.49% weight, market cap of 110.9 billion HKD) - Baijie Shenzhou (10.01% weight, market cap of 312 billion HKD) - Shiyao Group (9.97% weight, market cap of 102.1 billion HKD) [6][12]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin API prices are stabilizing, while iodine raw material prices are expected to rise in 2025 due to previous supply constraints [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, among others [8] - Weekly recommended stocks include Kanglong Chemical, WuXi AppTec, and Aopumai [8]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin raw material prices have stabilized after a period of decline, while iodine raw material prices are expected to rise again in 2025 due to increased demand [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, while weekly recommendations feature companies like Kanglong Chemical and Yao Ming He Lian [8]

在这一年的交易热潮中，跨国巨头们的采购风格各有不同。谁出手频次最高？谁手笔最大？经济观 察报分析了全年150多笔交易，复盘跨国药企的投资画像与交易特色。 多位受访者对经济观察报表示，其所在药企与潜在合作方达成了进一步沟通意向，他们判断2026 年中国创新药对外授权交易热仍会持续。 2025年爆发式增长的对外授权交易验证了中国创新药资产的价值，该年对外授权总交易额超1300 亿美元，交易数超150笔（约占全球40%），创下历史新高。 阿斯利康最活跃 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共出手了5次。 合作方包括石药集团（01093.HK）、和铂医药（02142.HK）、加科思药业（01167.HK）、元 思生肽等。其中，在2025年6月与石药集团达成的潜在总交易额超53亿美元的合作，可排进年度 交易额前四。在资产选择上，阿斯利康主要集中在临床早期管线，以及技术平台合作。 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共 出手了5次。从立即兑现的首付款看，辉瑞与武田制药出手最 阔绰。 作者：张英 封图：图虫创意 作为中国市场销售额最高的外资药企，在经历2024年的公司治理风暴后，阿斯利康 ...

Group 1: Overview of Guangdong Products - The "Guangdong Products Going Global" initiative is gaining momentum as the Spring Festival approaches, with a focus on promoting local goods both online and offline [3] - Guangdong products, ranging from traditional items like Guangzhou flower arrangements to innovative industrial and biopharmaceutical products, are becoming a significant part of the consumer market [3] - The success of Guangdong products is attributed to rich innovation stories and significant industry transformations [3] Group 2: Drone Industry - Guangdong's drone industry, exemplified by Chengzhi Intelligent, has seen significant growth, with products sold in over 50 countries [6] - Chengzhi Intelligent focuses on developing various drone payloads for emergency rescue and public safety applications, showcasing strong innovation and quality [7] - The company's products gained popularity through word-of-mouth and social media, highlighting the importance of innovation in global marketing [7] Group 3: Lighting and Home Appliances - The lighting industry in Zhongshan is evolving with a focus on customization and technology, moving from standardized to tailored products [10] - Companies are addressing market challenges by innovating and finding user pain points, demonstrating a commitment to quality and technological advancement [11] - The success of these companies is attributed to their ability to adapt and innovate within traditional sectors [11] Group 4: Biopharmaceutical Industry - The Guangdong biopharmaceutical sector is undergoing a transformation, moving from traditional herbal medicine to cutting-edge technologies that influence global health guidelines [13][15] - Companies like Dabo Biotech and Shiyao Mingfu are facing challenges in funding and regulatory processes, emphasizing the resilience required in the industry [14] - The government is responding to industry needs with new policies aimed at facilitating the development of innovative drugs [14] Group 5: Floral Industry - Guangzhou's floral industry is a significant economic contributor, with a market size exceeding 30 billion yuan and annual exports over 1.2 billion yuan [18][19] - Local representatives and businesses are actively promoting the floral industry, showcasing its potential for growth and innovation [20] - The collaboration among various stakeholders, including farmers and tech developers, is vital for sustaining the industry's vitality [20] Group 6: Film and Entertainment Industry - Guangdong's film industry is recognized as a leading market in China, supported by innovative practices in cinema operations and audience engagement [23] - The province's policy support for cultural industries has fostered a thriving environment for film production and creativity [24] - Recent successes in animation and film highlight the advancements in technology and storytelling within the Guangdong entertainment sector [24]

Core Insights - The 2026 JPMorgan Healthcare Conference highlighted significant interest from multinational companies in Chinese assets, particularly in the innovative drug sector [1][2] Group 1: Market Trends - The trend of foreign licensing deals for Chinese innovative drugs is expected to continue in 2026, following a record-breaking year in 2025 where the total licensing deal value exceeded $130 billion, accounting for approximately 40% of global transactions [3] - The surge in licensing deals in 2025 validated the value of Chinese innovative drug assets, with over 150 transactions recorded [3] Group 2: Key Players - AstraZeneca emerged as the most active multinational company in 2025, engaging in five transactions, including a notable deal with CSPC Pharmaceutical Group valued at over $5.3 billion [4] - Pfizer and Eli Lilly each conducted four transactions, with Pfizer's deal with 3SBio setting a record for upfront payments in Chinese innovative drugs at $1.25 billion [5] - GSK's collaboration with Heng Rui Medicine reached a potential total of $12.5 billion, marking the highest deal value for Chinese innovative drugs [13] Group 3: Emerging Markets - Interest in Chinese innovative drugs is not limited to Western companies; firms from India, Latin America, and the Middle East are also engaging in licensing deals [7] - Indian companies Glenmark and Dr. Reddy's each completed two business development transactions in 2025, with Glenmark's deals totaling over $2 billion [8][9] Group 4: Financial Highlights - Three companies, AstraZeneca, GSK, and Takeda, signed contracts exceeding $10 billion, while Pfizer and Novartis secured contracts over $5 billion [10] - The largest single transaction was GSK's deal with Heng Rui Medicine, which included rights to one core drug and options for 11 additional projects [13] Group 5: Future Outlook - Executives at the 2026 JPM conference expressed that Chinese assets are an effective way to supplement pipelines, indicating a shift towards acquiring entire biotechnology platforms rather than just single products [14]

Group 1: Guangdong Products and Market Trends - The "Guangdong Products Going Global" spring campaign is gaining traction, showcasing a variety of Guangdong goods that blend traditional craftsmanship with modern technology [2][4] - Guangdong's flower industry is a significant sector, with a market scale exceeding 30 billion yuan and an annual import-export value of over 1.2 billion yuan, making it the largest small potted plant production base in China [14][16] - The Guangdong film industry is experiencing growth, supported by government policies aimed at high-quality cultural development, which includes various sectors such as film and animation [44][45] Group 2: Innovation in Traditional Industries - The lighting industry in Zhongshan is shifting from standardization to customization, with companies focusing on technology-intensive solutions to meet diverse consumer needs [6][8] - Guangdong's biopharmaceutical sector is evolving from traditional herbal medicine to cutting-edge technologies, with companies like Kangfang Biotech achieving significant international milestones [28][30] - The drone industry in Guangdong is represented by companies like Chengzhi Intelligent, which has developed innovative products for emergency rescue operations, gaining popularity in over 50 countries [22][26] Group 3: Community and Collaborative Efforts - Local representatives and community members are actively promoting the flower industry, emphasizing the importance of collective efforts in sustaining the sector's vitality [16][19] - The Guangdong film industry benefits from collaboration among various stakeholders, including cinema operators and technology providers, enhancing the overall viewing experience [40][42] - The biopharmaceutical industry is seeing increased support from local governments, responding to the challenges faced by small and medium-sized biotech firms [32][34]

Market Overview - A-shares saw a collective rise on January 23, with the three major indices increasing and total trading volume exceeding 3 trillion yuan, up by 401.7 billion yuan from the previous day [1] - The photovoltaic sector surged, driven by Elon Musk's support for space photovoltaics, leading to a wave of limit-up stocks, including Longi Green Energy [1] - The commercial aerospace concept continued to soar, with ETFs related to general aviation and military industries also experiencing significant gains [1] Sector Performance - The photovoltaic sector saw a strong performance, with the only green energy ETF tracking the green energy index rising by 3.68% [1] - The general aviation ETF rose by 3.67%, marking a strong three-day rally, supported by multiple favorable catalysts [5][9] - The non-ferrous metals sector also performed well, with the non-ferrous ETF increasing by 3.37%, breaking through its listing high and attracting significant net subscriptions [1][9] AI and Technology - Nvidia's CEO compared AI to a "five-layer cake," emphasizing the importance of AI applications, which led to a 2.02% increase in the domestic AI ETF [2] - The entrepreneurial AI ETF saw a rapid increase in scale, growing from over 50 billion yuan to 60 billion yuan in just three trading days, becoming the largest AI ETF in the dual innovation track [2][20] Future Outlook - Guosen Securities maintains a bullish outlook for A-shares, citing favorable macroeconomic policies and expected inflows from long-term funds [4] - Huaxi Securities suggests focusing on three main investment lines: technology sector expansion, beneficiaries of "anti-involution" policies, and companies with high earnings growth forecasts [4] Commercial Aerospace Developments - The commercial aerospace and satellite navigation sectors are experiencing a resurgence, with significant stock price increases for companies like Ruichuang Micro-Nano and China Satellite [5][7] - The upcoming "Star Computing and Intelligent Connection" seminar is expected to further stimulate interest in the commercial aerospace market [7] Precious Metals - International gold prices have surged, reaching historical highs, driven by geopolitical risks and increased demand for safe-haven assets [11] - The non-ferrous metals sector is expected to continue its strong performance, supported by macroeconomic policies and structural changes in supply and demand [11]